| --- | --- | --- | --- | --- | |--------------------------|-------|-----------------------|-----------|-------------------| | | | | | | | | | | | | | | | | | | | Q1 FY24 February 1, 2024 | | Earnings Presentation | | | | | | | Advancing | the | | | | | | world of healthTM | Caution Concerning Forward-Looking Statements This presentation and accompanying audio webcast contain certain estimates and other forward-looking statements (as defined under federal securities laws) regarding BD's future prospects and ...

Becton, Dickinson and Company (NYSE:BDX) Q1 2024 Earnings Conference Call February 1, 2024 8:00 AM ET Company Participants Greg Rodetis - SVP, Treasurer & Head of IR Tom Polen - Chairman, President & CEO Christopher DelOrefice - EVP & CFO Michael Garrison - EVP & President, Medical Segment Dave Hickey - EVP & President, Life Sciences segment Conference Call Participants Rick Wise - Stifel Travis Steed - Bank of America Vijay Kumar - Evercore ISI Lawrence Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Patr ...

Becton, Dickinson and Company (BDX) , popularly known as BD, delivered adjusted earnings per share (EPS) of $2.68 in the first quarter of fiscal 2024, down 10.1% year over year. The figure topped the Zacks Consensus Estimate by 12.1%.The adjustments include expenses related to purchase accounting adjustments and integration costs, among others.GAAP EPS for the quarter was 96 cents, reflecting a decline of 43.5% from the year-earlier figure.Revenues in DetailBD registered revenues of $4.71 billion in the fis ...

For the quarter ended December 2023, Becton Dickinson (BDX) reported revenue of $4.71 billion, up 2.6% over the same period last year. EPS came in at $2.68, compared to $2.98 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $4.74 billion, representing a surprise of -0.64%. The company delivered an EPS surprise of +12.13%, with the consensus EPS estimate being $2.39.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

Becton Dickinson (BDX) came out with quarterly earnings of $2.68 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.13%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $3.42 per share when it actually produced earnings of $3.42, delivering no surprise.Over the last four quarters, t ...

Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced a strategic collaboration agreement with Techcyte. The tie-up aims to offer an artificial intelligence (AI)-based algorithm that guides cytologists and pathologists to efficiently and effectively identify evidence of cervical cancer and pre-cancer using whole-slide imaging.The Techcyte platform is compatible with liquid-based cytology preparations, including BD SurePath Liquid-based Pap Test vial. It also aims to be compatible w ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR For the transition period from to Commission file number 001-4802 Becton, Dickinson and Company (Exact name of registrant as specified in its charter) 1 Becton Drive, Franklin Lakes, New Jersey 07417-1880 (201) 847-6800 (Address of principal executive offices) (Zip Code) (Registrant's telephone number, including area code) | --- | --- | --- | |------------------------ ...

AI-Based Algorithm Aims to Enable Cytotechnologists and Pathologists to Efficiently Identify Evidence of Cervical Cancer and Precancerous LesionsFRANKLIN LAKES, N.J. and OREM, Utah, Jan. 30, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Techcyte, a world leader in artificial intelligence (AI)-based digital diagnostics, today announced a strategic collaboration agreement to offer an AI-based algorithm that guides cytologists and patholog ...

Becton Dickinson and Company (BDX) , popularly known as BD, is scheduled to report first-quarter fiscal 2024 results on Feb 1, before market open.In the last reported quarter, the company’s earnings per share (EPS) of $3.42 matched the Zacks Consensus Estimate. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and matched once, delivering an earnings surprise of 4.5%, on average.Let’s check out the factors that have shaped BDX’s performance prior to t ...

Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced its collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications coupled with robotics-compatible reagent kits.This collaboration is likely to enable greater standardization and reduce human error when conducting large-scale single-cell multiomics experiments.Price PerformanceFor the past six months, BDX’s shares have lost 17.2% compared with the indu ...